RAPH — Raphael Pharmaceutical Inc.
—
OTC ·
Materials ·
Chemicals ·
CIK 1415397 ·
Last close
$1.40
Market Cap
$28.25M
52W High
$1.40
52W Low
$1.40
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -223,000 | -229,000 | 3,000 | 1,000 | 1,665,000 |
| Dec 2025 | 0 | — | -254,000 | -273,000 | 53,000 | 45,000 | 1,486,000 |
| Sep 2025 | 0 | — | -251,000 | -255,000 | 7,000 | 3,000 | 1,271,000 |
| Jun 2025 | 0 | — | -315,000 | -322,000 | 30,000 | 20,000 | 1,078,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-210,000
Investing CF
$0
Financing CF
$236,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.06
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-10,168,000
Inventory
—
Receivables
$2,000
ST Investments
—
EBIT TTM
$-1,262,000
Pretax Income TTM
$-1,279,000
Interest Exp TTM
$11,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,245,000 | -1,279,000 | 53,000 | 1,486,000 | — | -210,000 |
| Dec 2024 | 0 | -1,509,000 | -1,519,000 | 27,000 | 769,000 | — | -532,000 |
| Dec 2023 | 0 | -1,332,000 | -1,344,000 | 239,000 | 132,000 | — | -1,203,000 |
| Dec 2022 | 0 | -3,317,000 | -3,358,000 | 333,000 | 227,000 | — | -759,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRMD | MARIMED INC. | $29.94M | $0.08 | — |
| BIOX | Bioceres Crop Solutions Corp. | $26.53M | $0.42 | — |
| UG | UNITED GUARDIAN INC | $32.62M | $7.10 | — |
| CXXIF | C21 Investments Inc. | $32.85M | $0.28 | — |
| KARX | Karbon-X Corp. | $22.16M | $0.25 | — |
News headlines (Yahoo Finance, 1h cache)
Markel Insurance appoints Raphael Da Costa to lead U.S. cyber and tech E&O portfolio
2026-05-07 12:00 · Yahoo
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
2025-11-17 17:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.